Estimates
Source: S&P Capital IQ consensus via Xpressfeed · Generated 2026-07-29.
The forward tape was marked down and has since steadied: FY2027 normalized EPS consensus sits at $7.35, down 9.6% from six months ago, and FY2028 at $8.60, down 9.3%, yet both are flat to marginally higher over the last 30 days. KKR kept beating through the markdown, topping normalized EPS consensus in seven of the last eight quarters and clearing both lines by more than 10% in the March 2026 quarter. What survived the cuts is still a steep curve: consensus carries FY2027 revenue up 18.8% and EPS up 20.2%. The depth behind that curve is uneven, with 22 analysts on the EPS line and six on revenue.
FY2027 EPS consensus is down 9.6% over six months but has stopped falling in the last 30 days
Currency: USD · Scale: money in millions, absolute · Point-in-time consensus; Δ90d is Now versus 90d.
| Metric | FY | 180d | 90d | 30d | Now | Δ90d |
|---|---|---|---|---|---|---|
| EPS (normalized) | FY2027 | $8.13 | $7.65 | $7.40 | $7.35 | -3.9% |
| EPS (normalized) | FY2028 | $9.48 | $8.57 | $8.59 | $8.60 | +0.3% |
| Revenue | FY2027 | $12.71bn | $12.30bn | $12.22bn | $12.28bn | -0.1% |
| Revenue | FY2028 | $15.08bn | $13.76bn | $13.70bn | $13.90bn | +1.0% |
Seven EPS beats in eight quarters, and the latest print cleared both lines by more than 10%
Current sequences by metric: Revenue: 1 consecutive beat; EPS (normalized): 1 consecutive beat.
Currency: USD · Scale: money in millions, absolute · Consensus is captured before each actual first became effective.
| Quarter | Metric | Consensus | Actual | Surprise | Outcome |
|---|---|---|---|---|---|
| Q1 FY2026 | Revenue | $2.11bn | $2.35bn | +11.2% | Beat |
| Q1 FY2026 | EPS (normalized) | $1.26 | $1.39 | +10.3% | Beat |
| Q4 FY2025 | Revenue | $1.78bn | $1.64bn | -8.4% | Miss |
| Q4 FY2025 | EPS (normalized) | $1.14 | $1.12 | -1.6% | Miss |
| Q3 FY2025 | Revenue | $2.26bn | $2.40bn | +6.3% | Beat |
| Q3 FY2025 | EPS (normalized) | $1.30 | $1.41 | +8.6% | Beat |
| Q2 FY2025 | Revenue | $1.84bn | $1.86bn | +0.8% | Beat |
| Q2 FY2025 | EPS (normalized) | $1.14 | $1.18 | +3.6% | Beat |
| Q1 FY2025 | Revenue | $1.71bn | $1.77bn | +3.3% | Beat |
| Q1 FY2025 | EPS (normalized) | $1.13 | $1.15 | +1.7% | Beat |
| Q4 FY2024 | Revenue | $1.96bn | $2.04bn | +4.0% | Beat |
| Q4 FY2024 | EPS (normalized) | $1.27 | $1.32 | +3.7% | Beat |
| Q3 FY2024 | Revenue | $1.75bn | $1.96bn | +12.3% | Beat |
| Q3 FY2024 | EPS (normalized) | $1.20 | $1.38 | +15.4% | Beat |
| Q2 FY2024 | Revenue | $1.62bn | $1.73bn | +7.0% | Beat |
| Q2 FY2024 | EPS (normalized) | $1.06 | $1.09 | +2.4% | Beat |
Even after the cuts, consensus carries FY2027 revenue up 18.8% and EPS up 20.2%
Growth decelerates modestly into FY2028 — revenue +13.2%, EPS +17.0% — while consensus ROE steps up in each of the three years. The EBITDA row rests on one to two analysts and should be read as indicative rather than as a street view.
Currency: USD · Scale: money in millions, absolute · YoY uses the prior fiscal year from the feed; analyst count and range use the first displayed period.
| Metric | FY2026E | FY2027E | FY2028E | YoY | Analysts | Low / high |
|---|---|---|---|---|---|---|
| Revenue | $10.34bn | $12.28bn | $13.90bn | +35.0% | 6 | $9.74bn / $10.89bn |
| EBITDA | $7.45bn | $9.02bn | $12.09bn | +25.0% | 2 | $6.55bn / $8.35bn |
| EPS (normalized) | $6.12 | $7.35 | $8.60 | +25.6% | 22 | $5.85 / $6.35 |
| ROE | 13.3% | 13.8% | 14.9% | +3.7pt | — | — |
Where the street disagrees
The FY2027 EPS range is about 15% of the mean on a 22-analyst line, so the dispersion is not a small-sample artifact. FY2027 revenue is slightly wider in percentage terms but rests on six analysts, and the FY2028 revenue range on three is closer to a sampling of models than a consensus.
Currency: USD · Scale: money in millions, absolute · Spread/mean is absolute high-low divided by absolute mean.
| Metric | Period | Mean | Low–high | Spread/mean | Analysts |
|---|---|---|---|---|---|
| EPS (normalized) | FY2027E | $7.35 | $6.75–$7.82 | 14.6% | 22 |
| Revenue | FY2027E | $12.28bn | $11.37bn–$13.40bn | 16.5% | 6 |
| EPS (normalized) | FY2028E | $8.60 | $7.76–$9.20 | 16.7% | 10 |
| Revenue | FY2028E | $13.90bn | $13.02bn–$14.53bn | 10.9% | 3 |
Coverage caution: this is an EPS consensus, not a full-model consensus
Normalized EPS carries 22 analysts in FY2026 and FY2027, but 10 in FY2028 and 2 in FY2029. Revenue has 6 analysts in FY2027 and 3 in FY2028, FY2028 EBITDA has 1, and the GAAP net income and EPS lines carry 1-2 throughout, with the FY2025 GAAP net income mean landing far from the reported actual. Treat anything outside the normalized EPS row as a small sample.